0R15 8520.0 -2.3383% 0R1E 8203.0 -0.4731% 0M69 21090.0 67.5139% 0R2V 229.3078 10023.9647% 0QYR None None% 0QYP 417.4 -1.7882% 0RUK 2652.0 -9.2402% 0RYA 1520.0 -2.8754% 0RIH 174.55 -1.3563% 0RIH 175.396 0.4847% 0R1O 204.45 10097.0075% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 164.23 1.7817%
Last update at 2024-11-21T14:54:00Z
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
Sat 02 Nov 24, 12:00 AMThe Ultimate Biotech Stock to Buy With $50 Right Now
Sat 26 Oct 24, 12:00 AMWe Think CRISPR Therapeutics (NASDAQ:CRSP) Can Easily Afford To Drive Business Growth
Sat 19 Oct 24, 02:36 PM3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Sat 19 Oct 24, 11:30 AMIs CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds?
Wed 16 Oct 24, 07:47 PMWhy I Keep Buying These 14 Incredible Growth Stocks
Wed 16 Oct 24, 01:45 PMCRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
Tue 15 Oct 24, 10:00 PMIs CRISPR Therapeutics Stock a Buy?
Sun 13 Oct 24, 12:00 AM2 Biotech Stocks That Are Screaming Buys This Month
Sat 12 Oct 24, 12:30 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -650.50000M | 379.53M | -348.05600M | 67.31M | -164.42800M |
| Minority interest | - | - | - | - | - |
| Net income | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Selling general administrative | 102.46M | 102.80M | 88.21M | 63.49M | 48.29M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | -109.81400M | 913.08M | 0.54M | 289.59M | 3.12M |
| Reconciled depreciation | 24.17M | 17.95M | 9.18M | 4.72M | 3.52M |
| Ebit | -697.33300M | 355.57M | -354.43500M | 42.02M | -162.46200M |
| Ebitda | -673.16100M | 373.53M | -345.25100M | 46.74M | -158.94300M |
| Depreciation and amortization | 24.17M | 17.95M | 9.18M | 4.72M | 3.52M |
| Non operating income net other | 22.66M | 6.00M | 6.38M | 20.57M | -5.48500M |
| Operating income | -673.16100M | 373.53M | -354.43500M | 46.74M | -158.94300M |
| Other operating expenses | 673.60M | 539.55M | 354.98M | 242.85M | 162.07M |
| Interest expense | -46.83300M | 23.96M | 6.38M | 25.29M | 0.00000M |
| Tax provision | -0.32500M | 1.87M | 0.81M | 0.45M | 0.55M |
| Interest income | - | - | - | 5.47M | 4.28M |
| Net interest income | - | - | - | - | 0.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.32500M | 1.87M | 0.81M | 0.45M | 0.55M |
| Total revenue | 0.44M | 913.08M | 0.54M | 289.59M | 3.12M |
| Total operating expenses | 563.35M | 539.55M | 354.98M | 242.85M | 162.07M |
| Cost of revenue | 110.25M | - | - | 179.36M | 113.77M |
| Total other income expense net | 22.66M | 6.00M | 6.38M | 20.57M | -5.48500M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Net income applicable to common shares | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2229.57M | 2243.06M | 2751.88M | 1827.97M | 1066.75M |
| Intangible assets | 0.02M | 0.07M | 0.12M | 0.18M | 0.23M |
| Earning assets | - | - | - | - | - |
| Other current assets | 14.39M | 37.71M | 38.08M | 26.14M | 43.68M |
| Total liab | 346.77M | 367.58M | 352.42M | 163.73M | 127.33M |
| Total stockholder equity | 1882.80M | 1875.48M | 2399.46M | 1664.23M | 939.42M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 50.91M | 65.51M | 91.90M | 71.46M | 41.71M |
| Common stock | 2.50M | 2.44M | 2.39M | 2.28M | 1.85M |
| Capital stock | 2.50M | 2.44M | 2.39M | 2.28M | 1.85M |
| Retained earnings | -999.70000M | -846.09000M | -195.91500M | -573.57600M | -224.71100M |
| Other liab | - | 18.29M | 19.66M | 19.41M | 26.17M |
| Good will | - | - | - | - | - |
| Other assets | - | 16.27M | 22.20M | 18.14M | 6.14M |
| Cash | 389.48M | 211.88M | 923.03M | 1168.62M | 943.77M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 108.79M | 121.11M | 119.88M | 94.26M | 57.11M |
| Current deferred revenue | 4.11M | 12.32M | 1.01M | 2.34M | 0.96M |
| Net debt | -150.84500M | 32.14M | -698.00100M | -1107.19100M | -891.23200M |
| Short term debt | 15.62M | 15.84M | 12.16M | 11.36M | 8.49M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 238.63M | 244.02M | 225.03M | 61.43M | 52.54M |
| Other stockholder equity | 2878.09M | 2734.78M | 2598.05M | 2235.62M | 1162.28M |
| Property plant equipment | - | 163.63M | 137.57M | 42.16M | 72.83M |
| Total current assets | 1908.08M | 1853.03M | 2417.51M | 1716.62M | 987.55M |
| Long term investments | 1.97M | 53.13M | - | - | - |
| Net tangible assets | - | 1875.48M | 2399.46M | 1664.05M | 939.19M |
| Short term investments | 1304.21M | 1603.43M | 1456.10M | 521.71M | - |
| Net receivables | 200.00M | 4.64M | 0.30M | 0.14M | 0.10M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 38.15M | 27.43M | 14.82M | 9.09M | 5.94M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 1.91M | -15.64700M | -5.06700M | -0.08300M | 0.00700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 2.44M | 2.39M | 2.28M | 1.85M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -846.09000M | -195.91500M | -573.57600M | -224.71100M |
| Treasury stock | - | -0.06300M | -0.06300M | -0.06300M | -0.06300M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 13.57M | 16.27M | 22.20M | 18.14M | 6.14M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 321.49M | 390.03M | 334.36M | 111.35M | 79.20M |
| Capital lease obligations | 238.63M | 244.02M | 225.03M | 61.43M | 52.54M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -258.65500M | -953.72500M | -522.81200M | 1.32M | -2.77300M |
| Change to liabilities | 3.64M | 32.21M | 15.24M | 30.01M | 12.36M |
| Total cashflows from investing activities | -258.65500M | -1035.43000M | -541.17000M | 1.32M | -2.77300M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 38.59M | 250.94M | 1016.15M | 430.98M | 315.93M |
| Change to operating activities | 15.39M | -9.71100M | 6.36M | -8.29800M | -3.80200M |
| Net income | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Change in cash | -715.88400M | -245.52400M | 236.66M | 489.00M | 216.90M |
| Begin period cash flow | 939.94M | 1185.47M | 948.81M | 459.81M | 242.91M |
| End period cash flow | 224.06M | 939.94M | 1185.47M | 948.81M | 459.81M |
| Total cash from operating activities | -495.74100M | 538.97M | -238.36600M | 56.68M | -96.23900M |
| Issuance of capital stock | 0.97M | 213.27M | 982.29M | 415.02M | 307.05M |
| Depreciation | 24.17M | 17.95M | 9.18M | 4.72M | 3.52M |
| Other cashflows from investing activities | - | - | - | 8.01M | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | -37.51400M | -25.74700M | -5.02500M | 332.30M |
| Change to account receivables | 0.30M | -0.16100M | -0.04500M | -0.01100M | 2.54M |
| Sale purchase of stock | 38.59M | 250.94M | 1016.15M | 430.98M | -0.05700M |
| Other cashflows from financing activities | 37.62M | 37.68M | 33.86M | 15.96M | 8.94M |
| Change to netincome | 110.42M | 102.39M | 67.88M | 49.52M | 34.82M |
| Capital expenditures | 37.19M | 81.70M | 18.36M | 6.68M | 2.77M |
| Change receivables | 0.30M | -0.16100M | -0.04500M | -0.01100M | 2.54M |
| Cash flows other operating | 15.90M | -5.18900M | 18.25M | -94.42700M | 15.51M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -715.80400M | -245.51300M | 236.62M | 488.99M | 216.92M |
| Change in working capital | 19.84M | 26.86M | 33.44M | -48.43000M | 10.55M |
| Stock based compensation | 97.95M | 102.39M | 66.02M | 44.06M | 34.98M |
| Other non cash items | 12.47M | 14.11M | 1.86M | -10.53300M | 15.41M |
| Free cash flow | -532.92900M | 457.27M | -256.72400M | 49.99M | -99.01200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRSP Crispr Therapeutics AG |
-1.055 2.23% | 46.20 | - | 23.36 | 13.87 | 2.73 | 9.99 | -18.2278 |
| NVO Novo Nordisk A/S |
-3.44 3.27% | 101.83 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.99 1.89% | 103.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.75 1.27% | 445.48 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-3.35 0.45% | 740.00 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Baarerstrasse 14, Zug, Switzerland, 6300
| Name | Title | Year Born |
|---|---|---|
| Dr. Samarth Kulkarni Ph.D. | CEO & Director | 1979 |
| Mr. Brendan Smith M.B.A. | Sr. VP, CFO & Principal Accounting Officer | 1976 |
| Dr. Lawrence Otto Klein Ph.D. | Chief Operating Officer | 1982 |
| Mr. James R. Kasinger | Gen. Counsel & Sec. | 1972 |
| Dr. Rodger Novak M.D. | Founder, Chairman & Pres | 1967 |
| Mr. Shaun Foy | Founder | NA |
| Dr. Emmanuelle Marie Charpentier | Co-Founder & Scientific Advisory Board Member | NA |
| Dr. Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member | NA |
| Dr. Chad A. Cowan Ph.D. | Scientific Founder | NA |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...